Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome

Hitoshi Kohno Dr., Yutaka Igarashi, Keiichi Ozono, Kenji Ohyama, Masamichi Ogawa, Hisao Osada, Kazumichi Onigata, Susumu Kanzaki, Yoshiki Seino, Hiroaki Takahashi, Toshihiro Tajima, Katsuhiko Tachibana, Hiroyuki Tanaka, Yoshikazu Nishi, Tomonobu Hasegawa, Kenji Fujieda, Keinosuke Fujita, Reiko Horikawa, Susumu Yokoya, Toru YorifujiToshiaki Tanaka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.

Original languageEnglish
Pages (from-to)29-34
Number of pages6
JournalClinical Pediatric Endocrinology
Volume21
Issue number2
DOIs
Publication statusPublished - 2012

Fingerprint

Turner Syndrome
Growth Hormone
Cholesterol
Therapeutics
Hyperinsulinism
Subcutaneous Injections
Dyslipidemias
Research
Type 2 Diabetes Mellitus
Japan
Obesity
Body Weight
Hypertension

Keywords

  • Growth hormone therapy
  • Serum cholesterol
  • Turner syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

Kohno Dr., H., Igarashi, Y., Ozono, K., Ohyama, K., Ogawa, M., Osada, H., ... Tanaka, T. (2012). Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome. Clinical Pediatric Endocrinology, 21(2), 29-34. https://doi.org/10.1297/cpe.21.29

Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome. / Kohno Dr., Hitoshi; Igarashi, Yutaka; Ozono, Keiichi; Ohyama, Kenji; Ogawa, Masamichi; Osada, Hisao; Onigata, Kazumichi; Kanzaki, Susumu; Seino, Yoshiki; Takahashi, Hiroaki; Tajima, Toshihiro; Tachibana, Katsuhiko; Tanaka, Hiroyuki; Nishi, Yoshikazu; Hasegawa, Tomonobu; Fujieda, Kenji; Fujita, Keinosuke; Horikawa, Reiko; Yokoya, Susumu; Yorifuji, Toru; Tanaka, Toshiaki.

In: Clinical Pediatric Endocrinology, Vol. 21, No. 2, 2012, p. 29-34.

Research output: Contribution to journalArticle

Kohno Dr., H, Igarashi, Y, Ozono, K, Ohyama, K, Ogawa, M, Osada, H, Onigata, K, Kanzaki, S, Seino, Y, Takahashi, H, Tajima, T, Tachibana, K, Tanaka, H, Nishi, Y, Hasegawa, T, Fujieda, K, Fujita, K, Horikawa, R, Yokoya, S, Yorifuji, T & Tanaka, T 2012, 'Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome', Clinical Pediatric Endocrinology, vol. 21, no. 2, pp. 29-34. https://doi.org/10.1297/cpe.21.29
Kohno Dr., Hitoshi ; Igarashi, Yutaka ; Ozono, Keiichi ; Ohyama, Kenji ; Ogawa, Masamichi ; Osada, Hisao ; Onigata, Kazumichi ; Kanzaki, Susumu ; Seino, Yoshiki ; Takahashi, Hiroaki ; Tajima, Toshihiro ; Tachibana, Katsuhiko ; Tanaka, Hiroyuki ; Nishi, Yoshikazu ; Hasegawa, Tomonobu ; Fujieda, Kenji ; Fujita, Keinosuke ; Horikawa, Reiko ; Yokoya, Susumu ; Yorifuji, Toru ; Tanaka, Toshiaki. / Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome. In: Clinical Pediatric Endocrinology. 2012 ; Vol. 21, No. 2. pp. 29-34.
@article{0953833df8974a97a62237834ffe4a26,
title = "Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome",
abstract = "Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.",
keywords = "Growth hormone therapy, Serum cholesterol, Turner syndrome",
author = "{Kohno Dr.}, Hitoshi and Yutaka Igarashi and Keiichi Ozono and Kenji Ohyama and Masamichi Ogawa and Hisao Osada and Kazumichi Onigata and Susumu Kanzaki and Yoshiki Seino and Hiroaki Takahashi and Toshihiro Tajima and Katsuhiko Tachibana and Hiroyuki Tanaka and Yoshikazu Nishi and Tomonobu Hasegawa and Kenji Fujieda and Keinosuke Fujita and Reiko Horikawa and Susumu Yokoya and Toru Yorifuji and Toshiaki Tanaka",
year = "2012",
doi = "10.1297/cpe.21.29",
language = "English",
volume = "21",
pages = "29--34",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",
number = "2",

}

TY - JOUR

T1 - Favorable impact of growth hormone treatment on cholesterol levels in turner syndrome

AU - Kohno Dr., Hitoshi

AU - Igarashi, Yutaka

AU - Ozono, Keiichi

AU - Ohyama, Kenji

AU - Ogawa, Masamichi

AU - Osada, Hisao

AU - Onigata, Kazumichi

AU - Kanzaki, Susumu

AU - Seino, Yoshiki

AU - Takahashi, Hiroaki

AU - Tajima, Toshihiro

AU - Tachibana, Katsuhiko

AU - Tanaka, Hiroyuki

AU - Nishi, Yoshikazu

AU - Hasegawa, Tomonobu

AU - Fujieda, Kenji

AU - Fujita, Keinosuke

AU - Horikawa, Reiko

AU - Yokoya, Susumu

AU - Yorifuji, Toru

AU - Tanaka, Toshiaki

PY - 2012

Y1 - 2012

N2 - Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.

AB - Background: Patients with Turner syndrome (TS) are prone to having metabolic abnormalities, such as obesity, dyslipidemia, hypertension, hyperinsulinemia and type 2 diabetes mellitus, resulting in increased risks of developing atherosclerotic diseases. Objective: To determine the effect of growth hormone (GH) therapy on serum cholesterol levels in prepubertal girls with TS enrolled in the Turner syndrome Research Collaboration (TRC) in Japan. Patients and methods: Eighty-one girls with TS were enrolled in the TRC, and their total cholesterol (TC) levels before GH therapy were compared with reported levels of healthy school-aged Japanese girls. TC levels after 1, 2 and 3 yr of GH treatment were available for 28 of the 81 patients with TS. GH was administered by daily subcutaneous injections, 6 or 7 times/wk, with a weekly dose of 0.35 mg/kg body weight. Results: Baseline TC levels revealed an age-related increase in TS that was in contrast to healthy girls showing unchanged levels. During GH therapy, TC decreased significantly after 1 yr of GH treatment and remained low thereafter. Conclusions: Girls with untreated TS showed an age-related increase in TC that was a striking contrast to healthy girls, who showed unchanged levels. GH therapy in girls with TS brought about a favorable change in TC that indicates the beneficial impact of GH on atherogenic risk.

KW - Growth hormone therapy

KW - Serum cholesterol

KW - Turner syndrome

UR - http://www.scopus.com/inward/record.url?scp=84862333660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862333660&partnerID=8YFLogxK

U2 - 10.1297/cpe.21.29

DO - 10.1297/cpe.21.29

M3 - Article

C2 - 23926408

AN - SCOPUS:84862333660

VL - 21

SP - 29

EP - 34

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

IS - 2

ER -